Ardsley Advisory Partners acquired a new stake in shares of Myovant Sciences Ltd (NYSE:MYOV) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 100,000 shares of the company’s stock, valued at approximately $1,272,000. Ardsley Advisory Partners owned about 0.16% of Myovant Sciences as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors and hedge funds also recently made changes to their positions in the company. JPMorgan Chase & Co. raised its position in shares of Myovant Sciences by 18.4% during the third quarter. JPMorgan Chase & Co. now owns 91,213 shares of the company’s stock valued at $1,382,000 after buying an additional 14,203 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in shares of Myovant Sciences during the third quarter valued at about $1,255,000. Finally, Goldman Sachs Group Inc. acquired a new position in shares of Myovant Sciences during the second quarter valued at about $174,000. 81.44% of the stock is owned by institutional investors and hedge funds.
Myovant Sciences Ltd (NYSE MYOV) opened at $16.92 on Tuesday. Myovant Sciences Ltd has a 52-week low of $9.92 and a 52-week high of $18.85. The company has a debt-to-equity ratio of 0.35, a current ratio of 5.04 and a quick ratio of 5.04. The stock has a market cap of $1,040.00 and a PE ratio of -8.63.
MYOV has been the subject of a number of research analyst reports. Cowen reaffirmed a “buy” rating on shares of Myovant Sciences in a research report on Tuesday, November 14th. Zacks Investment Research raised shares of Myovant Sciences from a “sell” rating to a “hold” rating in a research report on Wednesday, January 17th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company. Myovant Sciences has a consensus rating of “Buy” and a consensus price target of $22.50.
Myovant Sciences Company Profile
Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland.
Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.